668969-66-2

Usage

Uses

Used in Organic Synthesis:
2-(5-bromo-2-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile is used as a synthetic intermediate for the preparation of complex organic molecules. Its unique structure, including the nitrile functional group, allows for versatile reactions that can lead to the formation of a wide range of compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-(5-bromo-2-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile is used as a key building block in the development of new drugs. Its reactivity and the presence of the trimethylsilyl group can be exploited to create novel drug candidates with potential therapeutic applications.
Used in Material Science:
2-(5-bromo-2-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile is utilized as a component in the synthesis of advanced materials. 2-(5-bromo-2-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile's properties, such as its stability and reactivity, make it a candidate for creating new materials with improved characteristics for various applications.

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 

Downstream Products

• 1383983-00-3 5'-(3-chlorophenyl)-4-methoxy-5-methyldispiro[cyclohexane-1,2'-[1]benzofuran-3',2-imidazol]-4-amine 
• 1383985-07-6 (5-bromo-2-fluorophenyl)(1-hydroxy-4-methoxycyclohexyl)methanone 
• 1245516-26-0 4-(5-bromo-2-fluorobenzoyl)-4-hydroxycyclohexanone 
• 668969-65-1 (5-bromo-2-fluorophenyl)(hydroxy)acetic acid 

Relevant academic research and scientific papers

Discovery and structure-activity relationships of spiroindolines as novel inducers of oligodendrocyte progenitor cell differentiation

A novel series of spiroindoline derivatives was discovered for use as inducers of oligodendrocyte progenitor cell (OPC) differentiation, resulting from optimization of screening hit 1. Exploration of structure-activity relationships led to compound 18, which showed improved potency (rOPC EC50 = 0.0032 μM). Furthermore, oral administration of compound 18 significantly decreased clinical severity in an experimental autoimmune encephalomyelitis (EAE) model.

MONO-FLUORO BETA-SECRETASE INHIBITORS

Beta-secretase inhibitors, of formula (I) as described in the specification, pharmaceutical compositions comprising them and therapeutic methods using them for the treatment and/or prevention of Αβ-related pathologies such as Down's syndrome, β-amyloid an

Compounds and their use as BACE Inhibitors

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

INHIBITORS OF BETA-SECRETASE

The present invention relates to compounds represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.

ANTIBACTERIAL BENZOIC ACID DERIVATIVES

The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.